Table 1 Clinical features of patients and response to tocilizumab
Sample code | 37-5 | 37-7 | 50-2 | 50-4 | 51-1 | 51-3 | 53-2 | 53-4 |
Sample type | N | N | P, N | P, N | P, N | P, N | P, N | P, N |
Conditions | Pre-TOC | 12 weeks TOC | Pre-TOC | 12 weeks TOC | Pre-TOC | 12 weeks TOC | Pre-TOC | 12 weeks TOC |
Ethnicity | Caucasian | Caucasian | Asian | Caucasian | ||||
Gender | Male | Female | Male | Female | ||||
Age at onset (AAO) | 7 years | 9 years | 14 years | 4 years | ||||
Disease duration | 3.4 years | 7 years | 10 months | 9 months | ||||
Fever | Yes | No | No | No | No | No | Yes | No |
Rash | Yes | No | No | No | No | No | No | No |
Total WCC (lymphocytes) x 109/L | 22.22 (1.36) | 10.76 (4.99) | 10.51 (1.28) | 5.58 (2.67) | N/D | 5.84 (2.52) | 13.98 (4.80) | 8.09 (4.03) |
CRP (mg/l), 0-20 normal range | 84 | <5 | 24 | <5 | 13.6 | <3 | 56 | <5 |
ESR (mm/h), 0–10 normal range | 65 | <1 | 29 | 3 | N/D | 1 | 35 | <1 |
Joint active | 6 | 0 | 22 | 10 | 6 | 0 | 51 | 0 |
Joint limited motion | 6 | 0 | 30 | 12 | 7 | 0 | 49 | 3 |
Parental VAS | N/D | 0 | 6.8 | 1 | 2.8 | 0.4 | 5 | 2.2 |
Physician VAS | 5 | 0 | 8 | 4 | 3 | 1 | 8 | 0.4 |
CHAQ | 1.75 | 0 | 1.5 | 0.38 | 0 | 0 | 1.13 | 0.5 |
ACR | - | 90 | - | 90 | - | 90 | - | 90 |